Structural and kinetic analysis of drug resistant mutants of HIV-1 protease

被引:106
作者
Mahalingam, B
Louis, JM
Reed, CC
Adomat, JM
Krouse, J
Wang, YF
Harrison, RW
Weber, IT
机构
[1] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA
[2] NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA
来源
EUROPEAN JOURNAL OF BIOCHEMISTRY | 1999年 / 263卷 / 01期
关键词
drug resistance; HIV-1; aspartic protease; crystal structure;
D O I
10.1046/j.1432-1327.1999.00514.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutants of HIV-1 protease that are commonly selected on exposure to different drugs, V82S, G48V, N88D and L90M, showed reduced catalytic activity compared to the wild-type protease on cleavage site peptides, CA-p2, p6(pol)-PR and PR-RT, critical for viral maturation. Mutant V82S is the least active (2-20% of wild-type protease), mutants N88D, R8Q. and L90M exhibit activities ranging from 20 to 40% and G48V from 50 to 80% of the wild-type activity. In contrast, D30N is variable in its activity an different substrates (10-110% of wild-type), with the PR-RT site bring the most affected. Mutants K45I and M46L, usually selected in combination with other mutations, showed activities that are similar to (60-110%) or greater than (110-530%) wild-type, respectively. No direct relationship was observed between catalytic activity, inhibition, and structural stability. The mutants D30N and V82S were similar to wild-type protease in their stability toward urea denaturation, while R8Q, G48V, and L90M showed 1.5 to 2.7-fold decreased stability, and N88D and K45I showed 1.6 to 1.7-fold increased stability. The crystal structures of R8Q, K45I and L90M mutants complexed with a CA-p2 analog inhibitor were determined at 2.0, 1.55 and 1.88 Angstrom resolution respectively, and compared to the wild-type structure. The intersubunit hydrophobic contacts observed in the crystal structures are in good agreement with the relative structural stability of the mutant proteases. All these results suggest that viral resistance does not arise by a single mechanism.
引用
收藏
页码:238 / 245
页数:8
相关论文
共 36 条
[1]   Molecular basis of HIV-1 protease drug resistance: Structural analysis of mutant proteases complexed with cyclic urea inhibitors [J].
Ala, PJ ;
Huston, EE ;
Klabe, RM ;
McCabe, DD ;
Duke, JL ;
Rizzo, CJ ;
Korant, BD ;
DeLoskey, RJ ;
Lam, PYS ;
Hodge, CN ;
Chang, CH .
BIOCHEMISTRY, 1997, 36 (07) :1573-1580
[2]   STRUCTURAL BASIS OF DRUG-RESISTANCE FOR THE V82A MUTANT OF HIV-1 PROTEINASE [J].
BALDWIN, ET ;
BHAT, TN ;
LIU, BS ;
PATTABIRAMAN, N ;
ERICKSON, JW .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (03) :244-249
[3]   CRYSTALLOGRAPHIC R-FACTOR REFINEMENT BY MOLECULAR-DYNAMICS [J].
BRUNGER, AT ;
KURIYAN, J ;
KARPLUS, M .
SCIENCE, 1987, 235 (4787) :458-460
[4]   IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS [J].
CONDRA, JH ;
SCHLEIF, WA ;
BLAHY, OM ;
GABRYELSKI, LJ ;
GRAHAM, DJ ;
QUINTERO, JC ;
RHODES, A ;
ROBBINS, HL ;
ROTH, E ;
SHIVAPRAKASH, M ;
TITUS, D ;
YANG, T ;
TEPPLER, H ;
SQUIRES, KE ;
DEUTSCH, PJ ;
EMINI, EA .
NATURE, 1995, 374 (6522) :569-571
[5]   THE HIV-1 PROTEASE AS A THERAPEUTIC TARGET FOR AIDS [J].
DEBOUCK, C .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (02) :153-164
[6]  
GRINDE B, 1992, J BIOL CHEM, V267, P9481
[7]   KINETIC CHARACTERIZATION AND CROSS-RESISTANCE PATTERNS OF HIV-1 PROTEASE MUTANTS SELECTED UNDER DRUG PRESSURE [J].
GULNIK, SV ;
SUVOROV, LI ;
LIU, BS ;
YU, B ;
ANDERSON, B ;
MITSUYA, H ;
ERICKSON, JW .
BIOCHEMISTRY, 1995, 34 (29) :9282-9287
[8]   CHARACTERIZATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS WITH INCREASED RESISTANCE TO A C-2-SYMMETRICAL PROTEASE INHIBITOR [J].
HO, DD ;
TOYOSHIMA, T ;
MO, HM ;
KEMPF, DJ ;
NORBECK, D ;
CHEN, CM ;
WIDEBURG, NE ;
BURT, SK ;
ERICKSON, JW ;
SINGH, MK .
JOURNAL OF VIROLOGY, 1994, 68 (03) :2016-2020
[9]   Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases [J].
Hong, L ;
Treharne, A ;
Hartsuck, JA ;
Foundling, S ;
Tang, J .
BIOCHEMISTRY, 1996, 35 (33) :10627-10633
[10]  
JANDU SK, 1990, BIOCHEMISTRY-US, V29, P6265